Harnessing the Power of Regulatory T cells for Orca-T: a High-Precision Cell Immunotherapy for AML, MDS & ALL
Time: 11:30 am
day: Day Two AM Cell-Based Approaches
Details:
- Orca Bio is an allogeneic cell therapy company developing high-precision cell immunotherapies for hematological malignancies and autoimmune disorders
- Orca-T, Orca Bio’s lead investigational product, is a cell therapy that leverages highly purified regulatory T cells to control immune reconstitution. It’s currently being tested in a pivotal Phase 3 study, Precision-T
- Orca-T is intended to reduce complications and provide better outcomes for patients
- Given its clinical profile, Orca-T has the potential to deliver curative treatment to an even wider net of AML and MDS patients
